NetworkNewsBreaks – CytoDyn Inc. (CYDY) Appoints
Post# of 154141
(Total Views: 185)
Posted On: 12/12/2018 6:15:37 PM
NetworkNewsBreaks – CytoDyn Inc. (CYDY) Appoints Dr. Scott Kelly as Chairman of the Board
Biotechnology company CytoDyn (OTCQB: CYDY) today announced that its board of directors has appointed Scott A. Kelly, M.D., FAAPMR as its chairman. Dr. Kelly has served on CytoDyn’s board since April 2017, and he succeeds Anthony D. Caracciolo, who will continue to serve as a company director. “We are delighted to have Scott serve as our chairman of the board and look forward to supporting him in his new role,” CytoDyn President, CEO and Director of Nader Pourhassan stated in the news release. “Scott has been instrumental in our strategy to aggressively develop leronlimab (“PRO 140”) in certain immunology and oncology indications. He played a key role in our recent acquisition of ProstaGene, which provided CytoDyn with essential patents as well as insight into the role of CCR5 in metastatic cancer. He also was instrumental in our selection of metastatic triple-negative breast cancer as our first oncology indication. Under CytoDyn’s expanded development strategy, we are preparing to enroll breast cancer patients in our first oncology trial while in parallel advancing our clinical programs in HIV.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn (OTCQB: CYDY) today announced that its board of directors has appointed Scott A. Kelly, M.D., FAAPMR as its chairman. Dr. Kelly has served on CytoDyn’s board since April 2017, and he succeeds Anthony D. Caracciolo, who will continue to serve as a company director. “We are delighted to have Scott serve as our chairman of the board and look forward to supporting him in his new role,” CytoDyn President, CEO and Director of Nader Pourhassan stated in the news release. “Scott has been instrumental in our strategy to aggressively develop leronlimab (“PRO 140”) in certain immunology and oncology indications. He played a key role in our recent acquisition of ProstaGene, which provided CytoDyn with essential patents as well as insight into the role of CCR5 in metastatic cancer. He also was instrumental in our selection of metastatic triple-negative breast cancer as our first oncology indication. Under CytoDyn’s expanded development strategy, we are preparing to enroll breast cancer patients in our first oncology trial while in parallel advancing our clinical programs in HIV.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)